The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
Some time ago Opdivo beat Adcetris in an NCI trial, and now Bristol files.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
The company leaves the door open for Trodelvy pre-chemo, despite Ascent-07’s failure.
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
Global phase 2 data in TNBC look similar to earlier results in China.
The company might have blown Enliven out of the water.